Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes

Harveshp Mogal; Konstantinos Chouliaras; Edward A Levine; Perry Shen; Konstantinos I Votanopoulos

doi:10.3978/j.issn.2078-6891.2015.131

Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes

J Gastrointest Oncol. 2016 Feb;7(1):129-42. doi: 10.3978/j.issn.2078-6891.2015.131.

Authors

Harveshp Mogal¹, Konstantinos Chouliaras¹, Edward A Levine¹, Perry Shen¹, Konstantinos I Votanopoulos¹

Affiliation

¹ Division of Surgical Oncology, Department of General Surgery, Wake Forest University, Winston-Salem, NC, USA.

Abstract

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment option in selected patients with peritoneal dissemination from a variety of epithelial primaries. Even though a small proportion will be alive and potentially cured at 10 years, the majority will eventually develop recurrent disease. Repeat CRS/HIPEC is a valid consideration in a selected subpopulation of patients with isolated peritoneal recurrence. This review summarizes the data on patient selection, feasibility, limitations and outcomes of repeat CRS/HIPEC.

Keywords: Repeat cytoreduction; hyperthermic intraperitoneal chemotherapy (HIPEC).

Publication types

Review